Interestingly, HTR2B has been described as an oncogene in hepatocellular carcinoma (HCC), prostate, small intestine and breast cancers [7,8,9], but as a tumor suppressor in ovarian cancer [10]. Here, HTR2B is linked to hepatocellular carcinoma.